Optimizing rWTC-MBTA Vaccine Formulations, Dosing Regimens, and Cryopreservation Techniques to Enhance Anti-Metastatic Immunotherapy
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26031340 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Juan Ye und 9 weiteren Autor:innen. Beteiligte Einrichtung: Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Hauptthemen laut MEDLINE: Cancer Vaccines, Cryopreservation, Immunotherapy, Triple Negative Breast Neoplasms. Die Arbeit nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural NIH HHS, NIH HHS, National Cancer Institute of the National Institutes of Health.
Abstract (Originalsprache)
Metastatic cancer poses significant clinical challenges, necessitating effective immunotherapies with minimal systemic toxicity. Building on prior research demonstrating the rWTC-MBTA vaccine’s ability to inhibit tumor metastasis and growth, this study focuses on its clinical translation by optimizing vaccine composition, dosing regimens, and freezing techniques. The vaccine formula components included three TLR ligands (LTA, Poly I:C, and Resiquimod) and an anti-CD40 antibody, which were tested in melanoma and triple-negative breast cancer (TNBC) models. The formulations were categorized as rWTC-MBT (Mannan-BAM with LTA, Poly I:C, Resiquimod), rWTC-MBL (LTA), rWTC-MBP (Mannan-BAM with Poly I:C), and rWTC-MBR (Resiquimod). In the melanoma models, all the formulations exhibited efficacy that was comparable to that of the full vaccine, while in the “colder” TNBC models, the formulations with multiple TLR ligands or Resiquimod alone performed the best. Vaccine-induced activation of dendritic cell (DC) subsets, including conventional DCs (cDCs), myeloid DCs (mDCs), and plasmacytoid DCs (pDCs), was accompanied by significant CD80+CD86+ population induction, suggesting robust innate immune stimulation. An initial three-dose schedule followed by booster doses (3-1-1-1 or 3-3-3-3) reduced the metastatic burden effectively. Gradual freezing (DMSO-based preservation) maintained vaccine efficacy, underscoring the importance of intact cell structure. These findings highlight the potential of simplified formulations, optimized dosing, and freezing techniques in developing practical, scalable immunotherapies for metastatic cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
- NE1 Inc., New York, NY 10022, USA.
- Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA.
ORCID-Profile: Herui Wang, Samik Chakraborty, Mitchell Sun, Ondrej Uher
Förderung
- Intramural NIH HHS
- NIH HHS
- National Cancer Institute of the National Institutes of Health
- CRADA research plan with NE1 Inc.
Zitieren
APA
Ye, J., Wang, H., Chakraborty, S., Sang, X., Xue, Q., Sun, M., Zhang, Y., Uher, O., Pacak, K., & Zhuang, Z. (2025). Optimizing rWTC-MBTA Vaccine Formulations, Dosing Regimens, and Cryopreservation Techniques to Enhance Anti-Metastatic Immunotherapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26031340
Vancouver
Ye J, Wang H, Chakraborty S, Sang X, Xue Q, Sun M, et al. Optimizing rWTC-MBTA Vaccine Formulations, Dosing Regimens, and Cryopreservation Techniques to Enhance Anti-Metastatic Immunotherapy. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26031340
BibTeX
@article{Ye2025,
author = {Ye, Juan and Wang, Herui and Chakraborty, Samik and Sang, Xueyu and Xue, Qingfeng and Sun, Mitchell and Zhang, Yaping and Uher, Ondrej and Pacak, Karel and Zhuang, Zhengping},
title = {Optimizing rWTC-MBTA Vaccine Formulations, Dosing Regimens, and Cryopreservation Techniques to Enhance Anti-Metastatic Immunotherapy},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26031340}
}
EUVIMED